Other

Fair Value Measurement Disclosure

Amgen Fair Value Measurement Disclosure decreased by 4.2% to $792.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 10.0%, from $880.00M to $792.00M. Over 2 years (FY 2023 to FY 2025), Fair Value Measurement Disclosure shows a downward trend with a -13.0% CAGR.

Analysis

StatementBalance Sheet Statement
SectionOther
CategoryRisk
SignalContext dependent
VolatilityModerate
First reportedQ4 2015
Last reportedQ1 2026Apr 30, 2026

How to read this metric

Changes in this value reflect market volatility impacting the company's portfolio or changes in the composition of assets held at fair value.

Detailed definition

This metric aggregates the carrying amounts of assets and liabilities that are measured at fair value on a recurring or...

Peer comparison

Standardized across industries under GAAP/IFRS fair value hierarchy disclosures.

Metric ID: fair_value_measurement_disclosure

Historical Data

10 periods
 Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$1.09B$1.07B$1.03B$886.00M$1.02B$880.00M$1.02B$904.00M$827.00M$792.00M
QoQ Change-1.8%-4.2%-13.7%+15.3%-13.9%+15.8%-11.3%-8.5%-4.2%
YoY Change-6.4%-17.9%-0.8%+2.0%-19.1%-10.0%
Range$792.00M$1.09B
CAGR-13.3%
Avg YoY Growth-8.7%
Median YoY Growth-8.2%
Current Streak3 quarters decline

Fair Value Measurement Disclosure at Other Companies

Frequently Asked Questions

What is Amgen's fair value measurement disclosure?
Amgen (AMGN) reported fair value measurement disclosure of $792.00M in Q1 2026.
How has Amgen's fair value measurement disclosure changed year-over-year?
Amgen's fair value measurement disclosure decreased by 10.0% year-over-year, from $880.00M to $792.00M.
What is the long-term trend for Amgen's fair value measurement disclosure?
Over 2 years (2023 to 2025), Amgen's fair value measurement disclosure has grown at a -13.0% compound annual growth rate (CAGR), from $1.09B to $827.00M.
What does fair value measurement disclosure mean?
The total value of assets and liabilities that are reported at their current market price rather than historical cost.